Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 198–199 (2006)Cite this article

boxed-textTenenbaum A et al. (2005) Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 26: 2032–2038

Bezafibrate, a pan-PPAR agonist, might reduce and/or delay the development of new-onset diabetes in obese patients with coronary heart disease

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Prentice AM (2006) The emerging epidemic of obesity in developing countries. Int J Epidemiol 35: 93–99

    Article  Google Scholar 

  2. King H et al. (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414–1431

    Article  CAS  Google Scholar 

  3. Padwal R et al. (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28: 736–744

    Article  CAS  Google Scholar 

  4. Staels B and Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460–2470

    Article  CAS  Google Scholar 

  5. Muscat GE and Dressel U (2005) Cardiovascular disease and PPARδ: targeting the risk factors. Curr Opin Investig Drugs 6: 887–894

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine, Epidemiology and Preventive Medicine at the University of Maryland Medical Center, Baltimore, MD, USA

    Michael Miller

Authors
  1. Michael Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, M. Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity. Nat Rev Endocrinol 2, 198–199 (2006). https://doi.org/10.1038/ncpendmet0157

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0157

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing